Company Quick10K Filing
Sanofi
20-F 2018-12-31 Filed 2019-03-08
20-F 2017-12-31 Filed 2018-03-07
20-F 2016-12-31 Filed 2017-03-03
20-F 2015-12-31 Filed 2016-03-04
20-F 2014-12-31 Filed 2015-03-11
20-F 2013-12-31 Filed 2014-03-07
20-F 2012-12-31 Filed 2013-03-07
20-F 2011-12-31 Filed 2012-03-06
20-F 2010-12-31 Filed 2011-03-01
20-F 2009-12-31 Filed 2010-03-12

Sanofi Financials

SNY Metrics, Comps, Filings

Quarterly | Annual

Business

Sanofi is a leading global healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions.

◆ A product is referred to either by its international non-proprietary name (INN) or its brand name, which is generally exclusive to the company that markets it. In most cases, the brand names of our products, which may vary from country to country, are protected by specific registrations. In this document, products are identified by their brand names used in France and/or in the US.

◆ For our Pharmaceuticals activity, unless otherwise stated, all market share percentages and rankings are calculated based on consolidated national pharmaceutical sales data, excluding vaccines and in constant euros, on a September 2018 MAT (Moving Annual Total) basis. The data are mainly from IQVIA local sales audit supplemented by various other country-specific sources including Knobloch (Mexico), GERS (France) and HMR (Portugal).


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Quarterly)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Quarterly)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Bristol Myers Squibb (BMY) 82,160 70% 10.6 10% 57,433 39,679 24,173 16,837 5,680 7,151 76,061
Celgene (CELG) 72,111 96% 10.4 14% 41,363 29,276 16,982 16,354 5,880 7,734 80,796
GW Pharmaceuticals (GWPH) 45,954 89% -870.1 -8% 848 128 205 182 -64 -52 45,400
Allergan (AGN) 54,957 63% -241.2 -5% 122,925 38,486 15,818 9,949 -5,872 -316 76,270
Zoetis (ZTS) 60,799 51% 29.1 13% 11,272 8,594 6,150 3,124 1,461 2,252 65,484
Sanofi (SNY) 52,845 0% 111,408 0 0 0 0 52,184
Vertex Pharmaceuticals (VRTX) 43,431 87% 46.7 29% 7,515 2,261 3,620 3,135 2,144 857 40,027
Regeneron Pharmaceuticals (REGN) 32,266 0% 12.2 15% 13,939 3,435 7,622 0 2,144 2,539 30,869
Alexion Pharmaceuticals (ALXN) 23,581 92% 12.8 10% 14,815 4,448 4,736 4,359 1,470 1,874 23,912
Biomarin Pharmaceutical (BMRN) 12,700 79% 1,194.1 -1% 4,558 1,484 1,250 986 -39 11 13,147
Elanco Animal Health (ELAN) 9,964 52% 30.6 1% 8,824 3,336 3,083 1,611 94 393 12,004
Mylan (MYL) 10,768 34% 12.5 -0% 31,054 19,590 8,309 2,810 -4 1,882 23,458
Teva (TEVA) 7,142 43% -10.6 -7% 57,246 42,322 17,455 7,550 -3,961 -2,814 29,713
Sarepta Therapeutics (SRPT) 5,588 0% -7.9 -36% 1,702 707 365 0 -620 -576 4,529
Ionis Pharmaceuticals (IONS) 8,784 76% 17.4 15% 2,895 1,397 821 626 436 491 8,536
Sage Therapeutics (SAGE) 7,414 82% -10.7 -56% 1,204 123 5 4 -670 -670 7,152
Bausch (BHC) 7,760 0% 25.3 -1% 31,667 29,107 8,498 0 -266 1,216 30,774
Alnylam Pharmaceuticals (ALNY) 8,913 80% -9.7 -32% 2,542 935 169 135 -821 -820 7,987
Catalent (CTLT) 7,405 32% 23.8 2% 6,120 3,864 2,631 834 152 421 10,021
Jazz Pharmaceuticals (JAZZ) 7,549 21% 11.2 11% 5,528 2,473 2,056 441 609 762 8,530

Balance Sheet ($MM)2018-12-31
Cash661
Accounts Receivable
Inventory
PP&E
Assets111,408
Accounts Payable
Long-Term Debt
Liabilities
Stockholders' Equity
Income Statement ($MM)2018-12-31
Revenue
Cost of Revenue
Gross Profit
R&D
SG&A
Tax
Net Income
Cash Flow ($MM)2018-12-31
Cash Operating
Cash Investing
Cash Financing